The recognition of these properties along with the favorable pharmacological and physiochemical profile of minocycline including high lipophilic property, complete oral absorption [29], a long half life, clinically desired pharmacokinetic characteristics [30] and a good safety profile (average tolerated oral dose 400 mg/day) [31] led us to design the current study to profile this drug with respect to its effects on IL-6 and IL-6 signaling pathways in ovarian cancer. This evidence concerns the gene IL6 and ovarian carcinoma.